Tag: il-6

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior studies, including the landmark...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation,...
1. Tocilizumab was not superior to standard care after 15 days, for COVID-19 patients in serious condition. 2. Patients given tocilizumab had higher rates of mortality and adverse events, but shorter hospital stays compared to the standard care group. Evidence Rating Level: 1 (Excellent) Study rundown: The COVID-19 pandemic has resulted in nearly 100...